Sat Kartar Life Fund Raise of ₹33.8 Cr

Sat Kartar Life Earnings Call Transcript: Key Takeaways

Sat Kartar Life is pivoting from pure Ayurveda products to an integrated healthcare model, showing strong revenue growth but scaling back prior top-line guidance to prioritize margins.

Call

Guides 32% growth

Sat Kartar Life H1 FY27 Results: Net Profit ₹9.2 Cr, Up 26.0% YoY

Sat Kartar Life Ltd reported revenue from operations of ₹113.9 Cr (+26.4% YoY) and net profit of ₹9.2 Cr (+26.0% YoY) for H1 FY27.

Key figure

Net profit ₹9.2 Cr · +26.0% YoY

Sat Kartar Life Investor Presentation: Key Takeaways

H1 FY27 deck discloses no revenue, PAT or EBITDA figures. Balance sheet is debt-free with ₹18.7 Cr net cash. Growth is hospital-led: 30-bed Delhi unit at breakeven, 300 beds targeted by FY27-end.

Sat Kartar Life Results Update

Sat Kartar Life Limited reported H1 FY27 revenue growth of 26% and EBITDA growth of 48% via press release. Its first Ayurveda hospital reached operating breakeven.

Sat Kartar Life Other Announcement

Sat Kartar Life filed CARE Ratings' IPO proceeds monitoring report for half year ended September 2026. It shows nil deviation from objects, so no new event occurred.

Sat Kartar Life Convertible Warrants

Sat Kartar Life's EGM covered one special resolution to issue fully convertible warrants to promoter group on preferential basis. Voting results follow within two working days.

Sudarshan Pharma Industries Fund Raise of ₹72 Cr

Sudarshan Pharma's board approved up to Rs. 72 Crore of preferential convertible warrants for promoters Hemal and Sachin Mehta. Shareholder approval will be sought at an EGM.

Value

₹72.00 Cr

Flywings Simulator Training Centre Fund Raise of ₹68.2 Cr

Flywings Simulator's board approved Rs. 68.20 Crore fully convertible warrants on a preferential basis. Promoter Rupal Mandavia is allotted Rs. 25 Crore, subject to shareholder approval.

Value

₹68.20 Cr

Kanel Industries Fund Raise of ₹16.99 Cr

Kanel Industries' board approved a rights issue of 42.52 lakh equity shares at Rs.39.95 each. The issue aggregates about Rs.16.99 Crore, with record date 13 November 2026.

Value

₹16.99 Cr

Execution

Rights issue opens 23 November 2026 and closes 30 November 2026

Sudarshan Pharma Industries Fund Raise

Board approved issuing up to 72 Crore warrants to promoters on a preferential basis. Pricing per Reg 164 is pending, with no fixed rupee value stated.

GAIL (India) Fund Raise

GAIL Board approved in principle the IPO of subsidiary GAIL Gas Limited on Indian exchanges. GAIL will dilute its GGL equity up to 25%.

Gujarat Inject (Kerala) Fund Raise of ₹3 Cr

Gujarat Inject Kerala's board approved a Rs.3 Crore preferential warrant issue to public investors. Authorised capital will rise to Rs.17.63 Crore, subject to shareholder approval.

Value

₹3.00 Cr